vom 28.06.2018

Stefan Fröhling: Newly Appointed Acting Managing Director

Since April 2018, Professor Stefan Fröhling has been Acting Managing Director of NCT Heidelberg. With his appointment, he succeeds Professor Christof von Kalle, who will be facing new career challenges. Together with Professor Dirk Jäger, Medical and Managing Director of NCT Heidelberg, Stefan Fröhling is now in charge of the institution. “From day one, Christof von Kalle supported and promoted NCT Heidelberg with great motivation and personal commitment. For his achievements, we are much obliged to him,” Dirk Jäger says. “We are pleased about the appointment of Stefan Fröhling, who is a worthy successor to Christof von Kalle.

Stefan Fröhling heads the Molecular and Cellular Oncology group at DKFZ and NCT Heidelberg. One of his research focuses is to better understand the molecular structure of cancer cells and the resulting functional processes to detect novel potential therapeutic targets for cancer treatment. As senior physician and scientist, Stefan Fröhling also heads the NCT MASTER program of NCT Heidelberg and NCT Dresden: Broad molecular diagnostics shall help the NCT MASTER team finding new treatment approaches for young patients with advanced cancer diseases, or patients with very rare tumors being resistant to standard therapies.

Stefan Fröhling studied medicine at the universities of Marburg and Heidelberg. He obtained his doctorate at Heidelberg University and earned his habilitation in Ulm. Having been awarded a German Research Foundation (DFG) scholarship, Stefan Fröhling worked at Boston Harvard Medical School from 2005 to 2009. Subsequently, he worked as clinician scientist at Ulm University Hospital. Since 2012, he has been physician and scientist at DKFZ and Heidelberg University Hospital.

Stefan Fröhling is member of numerous national and international scientific networks including the German Consortium for Translational Cancer Research (DKTK), which is funded by the Federal Ministry of Education and Research (BMBF). “We will keep on working intensely to be able to provide as many patients as possible with individually tailored cancer treatments,” Stefan Fröhling says. “Vital prerequisites for achieving this goal are the development of tools for the comprehensive cellular, molecular and functional characterization of individual tumors, and the steady expansion of the range of clinical studies.”